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Low 1 <18 months Present Favorable or 
Unfavorable




Low 4S <12 months none Favorable
Low L2 < 18 months none 11q 
Low M < 18 months None None
Intermediate 2A/2B <12 months Present Favorable or 
Unfavorable












Intermediate 4S <12 months None Unfavorable






Intermediate MS <18 months Present or 
Absent
11q
High 2A/2B <18 months Present Favorable or 
Unfavorable
High L1/L2 <18 months Present Favorable or 
Unfavorable
High 4S < 12 months Present Favorable or 
Unfavorable






High MS <18 months Present 11q
Table	1:	Risk	Group	and	Stages	of	Neuroblastoma	
Nursing Implications
Nurses	are	responsible	for	checking	each	patients chemotherapy	
road	map	with	a	second	Chemo	Certified	Registered	Nurse.	The	purpose	
of	the	road	map	is	to	verify	that	the	medications	being	administered		
are	appropriate	during	the	specific	week	of	chemotherapy	they	are	in.	
Each	patient	has	their	own	precise	configuration	of	chemotherapy	
agents	specific	to	their	tumor	growth,	presence	or	absence	of	
metastasis	and	the	impending	side	effects.	Infection,	bleeding,	and	
mucositis	are	three	main	symptoms	to	monitor	closely	during	all	stages	
of	their	treatment	plan.	
Continuous	monitoring	of	each	patients blood	count,	pain	control,	
electrolyte	and	hydration	status	are	key	responsibilities	of	Nurses	
caring	for	children	with	Neuroblastoma	due	to	all	the	side	effects	of	
their	treatments	and	the	aggressiveness	of	the	tumor	cells.	Observing	
the	patient	after	initiation	of	treatment	for	adverse	effects	and/or	
allergic	reactions	will	allow	their	treatment	to	be	adjusted	to	better	
treat	their	tumor	with	lesser	adverse	effects.
Image	1:	Metastatic	Neuroblastoma	of	the	upper	tibia	and	lower	
femur,	(Adrenal	Gland:	Widely	Metastatic	Neuroblastoma	in	a	4	
year	old boy,	(2008)[image])
Treatment
Imaging
• Chest/abdominal	x	ray
• CT	of	primary	site	and	full	body	scan	for	metastasis	
• MRI	determines	if	the	tumor	is	intraspinal	or	causing	spinal	
cord	compression
• MIBG	scan	identify	primary	and	metastatic	tumor
• Bone	scans	evaluate	if	tumor	cells	metastasized	to	the	bone
• Skeletal	survey	will	display	metastatic	lesions
Surgery	
• Biopsies	of	the	tumor	site	and	surrounding	tissue
• First	line	cure	for	localized	tumors	
• Metastasized	tumors	require	biopsy	for	diagnosis	and	
staging
• Resection	following	chemotherapy
Radiation
Chemotherapy	is	based	on	the	stage	of	tumor	cell	growth	and	
how	the	medication	will	affect	tumor	growth.
• Antineoplastics interfere	with	cell	production
• Colony	Stimulating	factors	are	used	in	combination	with	
other	medications	to	prevent	neutropenia
• Chemoprotective	agents	are	included	in	the	medication	
regimen	to	minimize	side	effects	of	the	chemo
Statistics
• Most	common	cancer	in	children	
under	the	age	of	1	year	old
• 50-60%	if	children	experience	
metastasis.
• Occurs	more		in	White,	Non-
Hispanic	boys	
• Neuroblastoma	is	6%	of	all	
childhood	cancers
• 800	new	cases	per	year
• 90%	of	children	are	diagnosed	by	
age	5,	rarely	found	in	children	
over	10	years	old
• 75%	of	children	already	have	
lymph	node	involvement	when	
diagnosed
Conclusion
Neuroblastoma	is	an	aggressive	
cancer	affecting	nearly	800	newly	
diagnosed	children	per	year,	(Key	
Statistics,	2020).	The	pathogenesis	
is	studied	at	a	cellular	level	in	
utero	to	the	development	of	
multiple	different	pathways,	and	
the	ability	to	metastasize	to	
different	areas	of	the	body.	In	
every	2	out	of	3	cases,	lymph	node	
involvement	was	present	at	the	
time	of	diagnosis.	From	a	genetic	
or	chromosomal	level,	to	the	
maturation	of	an	immature	cell	
forming	a	solid	malignant	mass,	
each	Neuroblastoma	case	displays	
different	side	effects	requiring	
different	treatment	combinations	
and	interventions.	By	improving	
diagnosis	and	discovering	a	
different,	more	effective	pathway,	
early	detection	and	interventions	
may	decrease	incidence	rates	of	
Neuroblastoma	in	children.	
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